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Abstract
Spectrins line the intracellular surface of plasmalemma and play a critical role in supporting cytoskeletal stability and
flexibility. Spectrins can be proteolytically degraded by calpains and caspases, yielding breakdown products (SBDPs) of
various molecular sizes, with SBDP120 being largely derived from caspase-3 cleavage. SBDPs are putative biomarkers for
traumatic brain injury. The levels of SBDPs also elevate in the brain during aging and perhaps in Alzheimer’s disease (AD),
although the cellular basis for this change is currently unclear. Here we examined age-related SBDP120 alteration in
forebrain neurons in rats and in the triple transgenic model of AD (36Tg-AD) relative to non-transgenic controls. SBDP120
immunoreactivity (IR) was found in cortical neuronal somata in aged rats, and was prominent in the proximal dendrites of
the olfactory bulb mitral cells. Western blot and densitometric analyses in wild-type mice revealed an age-related elevation
of intraneuronal SBDP120 in the forebrain which was more robust in their 36Tg-AD counterparts. The intraneuronal
SBDP120 occurrence was not spatiotemporally correlated with transgenic amyloid precursor protein (APP) expression, b-
amyloid plaque development, or phosphorylated tau expression over various forebrain regions or lamina. No
microscopically detectable in situ activated caspase-3 was found in the nuclei of SBDP120-containing neurons. The
present study demonstrates the age-dependent intraneuronal presence of an aII-spectrin cleavage fragment in mammalian
forebrain which is exacerbated in a transgenic model of AD. This novel neuronal alteration indicates that impairments in
membrane protein metabolism, possibly due to neuronal calcium mishandling and/or enhancement of calcium sensitive
proteolysis, occur during aging and in transgenic AD mice.
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Introduction
Spectrins were first discovered in red blood cells and have
since been identified to be ubiquitously expressed, including in
neurons and glia [1],[2],[3],[4],[5],[6],[7],[8]. The spectrin
family of proteins includes a group of closely related gene
products that assemble as tetramers of a and b subunits to form
a pentagonal or hexagonal submembranous meshworks by
cross-linking with other proteins such as actin, protein 4.1 and
ankyrin. Spectrin filaments are essential for cells to maintain
stability of the membrane bilayer and cytoskeleton [3],[6].
These proteins also participate in assembly of specialized
membrane domains during dynamic membrane remodeling
events, such as cell migration, neuritic outgrowth and synapto-
genesis, therefore allowing membranous and cytoskeletal flexi-
bility that may be vital for neuronal and synaptic plasticity
[9],[10],[11],[12],[13],[14],[15],[16],[17]. The spectrin gene
family has expanded during evolution: one a and two b genes
code spectrin subunits in invertebrates, whereas two a spectrins
(aI and aII) and five b spectrins (bI to V) code the spectrin
family proteins in vertebrates, including human [6].
Spectrins can be degraded proteolytically by enzymes, including
calpains and caspases. During apoptotic and necrotic cell death,
calpain-specific cleavage of aII-spectrin yields 145 kDa and
150 kDa breakdown products (SBDPs), namely SBDP145 and
SBDP150. Caspase-3 mediated aII-spectrin proteolysis results in
the release of SBDP120 and SBDP150 fragments [18],[19]. Thus,
specific antibodies detecting these breakdown products can help
differentiate cell death models [20],[21],[22],[23],[24]. Studies
have shown SBDP elevation in the brain under acute and subacute
conditions associated with neuronal stress, injury and death,
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8including traumatic brain injury [21],[24], chemical neurotoxicity
[25], hypoxia [26] and ischemia [27].
Alterations in spectrin metabolism appear to occur in the body
as well as the brain during normal aging as well as age-related
chronic neurodegenerative diseases [28–34]. Specifically, spectrin
cleavage fragments (150 kDa) and abnormal spectrin immunore-
activity have been shown in the brains of Alzheimer’s disease (AD)
patients [35]. One study also demonstrated accumulation of
SBDP120 in cortical pyramidal neurons in AD, but not age-
matched control, brains [36]. More recently, levels of SBDP145
and SBDP150 were found to be elevated in both CSF and brain in
AD patients, as well as in transgenic models of AD [37],[38],
suggesting the potential use of SBDPs as novel biomarkers for this
disease [34].
Transgenic rodent models may be useful to explore the cellular
and molecular basis underlying SBDP alterations in AD.
Currently, little is known about the time course and cellular
localization of SDBP appearance in the aged brain. Further, it is
unclear if SDBPs are associated in any manner with the principal
AD lesions, i.e., a-amyloid plaques or tau pathology. Using a novel
and specific antibody, we identified the presence of SBDP120 in
forebrain neurons beginning around mid-age in wild-type mice. In
the triple transgenic mouse model of AD (36Tg-AD) [39],
SBDP120 expression occurred earlier and was more robust. The
age-related SBDP120 intraneuronal labeling in 36Tg-AD mice
did not correlate anatomically or temporally with the development
of extracellular amyloid plaques or tau pathology.
Materials and Methods
Ethics Statement
Experimental use of rats and mice in the present study was in
accordance with the National Institutes of Health Guide for the
Care and Use of Laboratory Animals. All experimental procedures
used the present study were approved by the Ethics Committee for
Animal Use at Central South University and by the Animal Care
and Use Committee of Southern Illinois University at Carbondale.
Animals and Tissue Preparation
Sprague-Dawley rats at 16 (n=4) and 24–26 (n=5) months of
age, and in-house bred 36Tg-AD mice and non-Tg controls at 6,
12, 18 and 24 months of age (n=8/age point/genotype) were
examined in the present study [40]. Animals were perfused
transcardially under terminal anesthesia (sodium pentobarbital,
100 mg/kg, i.p.) with cold 0.01 M phosphate-buffered saline
(pH 7.4, PBS). Brains were then quickly removed from the skull
and bisected along the midline. One hemi-brain was snap-frozen
with liquid nitrogen and stored at 270uC for western blot analysis.
The other hemi-brain was fixed by immersion in 4% paraformal-
dehyde in 0.01 M phosphate buffer for neuroanatomical studies.
After fixation for two days, the tissue was transferred into 30%
sucrose in 0.01 M phosphate buffer and stored at 4uC until it sank.
The brains were then cut into consecutive sets of coronal or
sagittal sections at either 30 micron- (12 sets, stored in
cryoprotectant at 220uC) or 6 micron- (12 sets, thaw-mounted
on slides, stored at 220uC) thickness using a cryostat (Microm
HM525, Germany). Markers (small cortical cuts or needle holes)
were made before or during brain sectioning and were recorded
for individual brains of different age groups. The 30 micron-thick
sections were used for immunodetection of SBDP120, 6E10,
phosphorylated-tau (p-Tau) or active caspase-3 with the avidin-
biotin complex (ABC) method. In order to eliminate potential
inter-experimental variability in immunolabeling, brain sections
from a group of animals at different ages were batch-processed
throughout the immunohistochemical procedure.
Primary Antibodies
The rabbit anti-SBDP120 antibody was generated using a
synthetic peptide (SVEALIKKHE) corresponding to the caspase-3
cleavage sequence (a.a.1478–1488) of aII spectrin. The final
working dilution was set at 1:400 by pilot antibody titration
immunohistochemical tests. The specificity of this rabbit SBDP120
antibody was characterized in the current study by preabsorption
of the primary antibody with the immunogenic peptide as well as
by omission of the primary and secondary antibodies during
immunohistochemistry procedures. Other primary antibodies
employed were a mouse anti-b-amyloid peptide (Ab) monoclonal
antibody 6E10 (#39320, Signet, 1:4000), a mouse anti-human
phosphorylated tau (p-Ser396/Ser404) monoclonal antibody
(PHF1, courtesy of Dr. P Davis, 1:4000) and rabbit anti-active
caspase-3 (#559565, BD Biosciences, 1:2000) [40],[41].
Immunohistochemistry
Sections (30 microns thick) were treated with 1% H2O2 in PBS
for 30 minutes, then pre-incubated in 5% normal horse serum
with 0.1% Triton X-100 for 1 hour. Sections were subsequently
incubated overnight at 4uC with primary antibodies at pre-
optimized concentrations in PBS containing 5% normal horse
serum and 0.1% Triton X-100. Following incubation with a
primary antibody, the sections were reacted with a biotinylated
pan-specific secondary antibody at 1:400 for 1 hour, and then in
freshly prepared avidin-biotin complex (ABC) solution (1:400)
(Vector Laboratories, Burlingame, CA) for another hour. Immu-
noreactivity was visualized using 0.003% H2O2 and 0.05%
diaminobenzidine (DAB). All incubations were followed by three
10 minute washes; after DAB development the sections were
dehydrated and mounted. Some immunolabeled sections were
counterstained with toluidine blue before mounting. For the
purpose of densitometry (to define the levels of non-specific
reactivity), brain-level matched sections were processed along with
the experimental sections, but without the exposure to the primary
antibody.
Western Blot
Frontal cortical blocks (containing the anterior ,J of a
hemisphere and olfactory bulbs) were separated from frozen hemi-
brains, weighed and homogenized by sonication in T-PER buffer
(106w/v) (Pierce, Rockford, IL) containing protease inhibitors
(Roche, Indianapolis, IN). After centrifugation at 15,0006g at 4uC
for 10 minutes, the supernatants were collected, followed by
determination of protein concentration by DC protein assay (Bio-
Rad Laboratories, Hercules, CA). Samples containing a total of
50 mg protein were run on a 4–20% SDS-PAGE gel (Bio-Rad
Laboratories). The polypeptides were then electrotransferred into
Trans-BlotH pure nitrocellulose membranes (Bio-Rad Laborato-
ries) and immunoblotted for SBDP120 (1:1000) or a-actin (1:5000,
Millipore, #04-1116). Immunoblotted protein products were
visualized using HRP-conjugated goat anti-rabbit IgG (1:20000,
Bio-Rad Laboratories) and the ECL Plus
TM Western Blotting
Detection kit (GE Healthcare Life Sci., Piscataway, NJ). Immu-
noblot images were analyzed using a SI PhosphorImager (Model
475, Molecular Dynamics, GE Healthcare).
Imaging, Data Analysis, Statistic Testing
Sections were examined on an Olympus (BX53) fluorescent
microscope equipped with a digital camera and image analysis
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were taken using 4X to 40X objective lens (with a 10X ocular
lens). For densitometric analysis, images were captured with the
20X objective lens using the same exposure setting for all brain
groups. Optical densities over layers II-VI of the frontal cortex,
and the mitral cell layer (MCL) together with the external
plexiform layer (EPL) of the olfactory bulb, were measured with
OptiQuant analysis software using the irregular-connecting
sampling tool (Packard Instruments, Meriden, CT). For a given
brain, optical densities were obtained from the three most medial
sagittal sections (,300 mm apart from each other), followed by a
calculation of the average density. Row data were imported into
and further processed with Microsoft Excel. Specific optical
densities were calculated by subtracting a mean background
density from total measured densities in a given area. The mean
background density was the average of nonspecific reactivity
readings obtained over the cortex and olfactory bulb in sections
processed without the primary antibody. Means of specific optical
density (o.d.) or normalized levels of specific o.d. between/among
comparing groups were analyzed statistically using one-way
ANOVA with Bonferroni posttests (Prism GraphPad 4.1, San
Diego, CA). The minimal significance level was set at p,0.05.
Figure panels were assembled using CorelDRAW 10.0, and then
converted into TIFF format.
Results
Characterization of SBDP120 Immunoreactivity in Aged
Rat Forebrain
SBDP120 antibody labeling was examined in brain sections
from 16 and 24–26 month-old rats because our pilot study did not
detect labeling in the cerebral cortex of 4- and 8-month old
animals. SBDP120 IR in the frontal cortex of 24–26 month-old
rats, most prominently in layer V (Fig. 1A). To determine the
specificity of the labeling, adjacent sections were stained in parallel
with and without the inclusion of the immunogenic peptide in the
primary antibody incubation buffer. The SBDP120 labeling was
largely absent in sections processed in the presence of either the 5-
mer or 8-mer synthetic immunogenic peptide at 0.1 mM
concentration (Fig. 1B, C). When both forms of peptide
(0.1 mM) were added, the specific IR was completely eliminated
(Fig. 1D). No cellular labeling existed in parallel batches of sections
that were processed by excluding either the primary (Fig. 1E) or
the secondary (Fig. 1F) antibody.
The pattern of SBDP120 IR in the cerebral cortex, hippocam-
pal formation and olfactory bulb was compared in 16 and 24–26
month-old rats (Fig. 2). In 16 month-old aged rats (Fig. 2A–J) a
small number of labeled profiles were seen in layer V across the
cortex along the rostrocaudal dimension (Fig. 2A, B). At higher
magnification these profiles appeared as small dot- or granule-like
elements that were seemingly arranged along the border of
neuron-like somatic profiles (Fig. 2B, E), rather than in the nucleus
or cytoplasm. No apparent SBDP120 IR was visible in the
hippocampal formation at low magnification (Fig. 2A), although a
few labeled granular elements were detectable in stratum pyrami-
dale (s.p.) of CA1 and CA3 at higher magnification (Fig. 2C, D, F,
G). Fairly distinct SBDP120 IR occurred selectively in the outer
areas of the olfactory bulb, arranged as a row of irregularly-shaped
elements approximately along the mitral cell layer (Fig. 2H). At
higher magnifications, the labeling at this location also appeared as
granules, tending to aggregate at the peripheral pole and/or in the
apical dendrites of a subpopulation of mitral cells (Fig. 2I, J),
including a few displaced mitral cells or tufted cells in the external
plexiform layer (Fig. 2I, marked with an asterisk).
Overall, the regional and laminar pattern of SBDP120 IR in the
forebrain of 24–26 month-old rats (Figs. 1A, 2K–N) was
comparable to that seen in 16 month-old animals. However, the
amount and intensity of labeling in the cortex and olfactory bulb
increased in the brains of the older rats (compare Figs. 1A and 2B).
The shape, size and intensity of the labeled profiles varied
considerably. Relatively larger or more heavily stained elements
appeared to arrange as perikaryal profiles, as was clearly seen in
sections counterstained with toluidine blue (Fig. 2K, L). The
immunolabeling product appeared to occur intracellularly in
addition to being arranged around the cell border (Figs. 1A, 2L).
The intracellular labeling was granular, and in many cases
condensed unevenly in pyramidal-like neurons (Fig. 2K, L). The
apical dendrites of some pyramidal somata were sometimes also
lightly labeled. Isolated immunoreactive elements were seen
distant from toluidine-stained cell nuclei, suggestive of neuronal
process labeling (Fig. 2K, L, arrowheads). In the olfactory bulb,
heavily labeled profiles resided around, or slightly peripheral, to
the mitral cell layer (Fig. 2M). These were composed of aggregated
granules grouped in fusiform, rod and irregular shapes (Fig. 2N).
In addition, some radially-oriented elements were scattered across
the external plexiform layer (Fig. 1M), with fewer and smaller
immunoreactive profiles also present near the glomeruli (Fig. 1M).
An increased diffuse labeling was noticeable in the olfactory
glomeruli in 24–26 month-old, relative to 16 month-old, rats
(compare Figs. 2H and 2M).
SBDP120 Immunoreactivity in Wild Type and 36Tg-AD
Mouse Forebrain
Overall, an age-related increase of localized SBDP120 im-
munolabeling was observed in both 36Tg-AD and non-Tg mouse
forebrain, but the increase was more prominent in the former
(Figs. 3 and 4). Very few SBDP120 immunoreactive elements were
seen in non-Tg mouse cortex until 12 months of age (Fig. 3A, E, I).
However, many labeled elements were present in layers V and VI,
and to a lesser extent in layers II and III, in 24-month old non-
transgenics (Fig. 3B, F, J). In the 36Tg-AD mice, some SBDP120
expressing elements were detectable in the cortex as early as 6
months of age (not shown). The immunoreactive elements were
consistently detected in deep cortical layers (IV–VI) in 12-month
old transgenics (Fig. 3C, G, L). These further increased by 18
months (not shown), and became abundant by 24 months of age
(Fig. 3D, H, M). At high magnification the labeling appeared
largely granular, often grouped seemingly along the peripheral
border of cortical cells at younger age points (Fig. 3J, L). However,
the labeling was also clearly present in the somata of a
subpopulation of pyramidal neurons in 24-month old transgenics
(Fig. 3M).
The development of intracellular aggregation of the labeled
granules in cortical pyramidal neurons could be appreciated by
comparing the labeling pattern between ages as well as genotypes
(Fig. 3I–M). Age and genotype differences in labeling pattern and
intensity could be easily seen in pseudocolor images subjected to a
background cutoff at the level of non-specific labeling (obtained
from sections that were processed in the absence of primary
antibody; Fig. 3N). Densitometric analysis confirmed that the
specific optic density of SBDP120 IR was significantly higher in
the transgenics relative to non-Tg groups at 12 (p,0.05,
Bonferroni posttests, same test below) and 24 months (p,0.05)
of age (Fig. 3O). There were also statistically significant differences
in specific optic density between 12 and 24 months of age for both
the transgenics (p,0.05) and non-transgenics (p,0.001, one-way
ANOVA, F=38.8, df=3, 12).
SBDP120 in Rodent Forebrain
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olfactory bulb, mostly impressive around the MCL (Fig. 4).
Most mitral cells, and likely the tufted cells as well (sparsely
distributed large cells in the EPL and between glomeruli),
expressed faint and diffuse SBDP IR in both the non-Tg and
36Tg-AD bulbs (Fig. 4A–L). In addition to this light labeling, a
few mitral cells in non-Tg brains contained strong immunore-
active granular elements at 12 months of age (Fig. 4B, arrows).
These elements were increasingly seen in mitral cells at 18 and
24 months in both the cell body (often around the peripheral
pole) and the proximal apical dendrites (Fig. 4C, D, J). In
36Tg-AD mice, SBDP120 immunoreactive granules were
already present in many mitral cells by 6 months of age
(Fig. 4E, K). These elements tended to progressively accumulate
and condense in the somata and proximal dendrites of the
mitral cells from 12 to 24 months of age (Fig. 4F–H, L). As a
result, most mitral cells contained heavily immunoreactive
granules that accumulated at the apical dendrites in the 24
month-old 36Tg-AD mice which, in some cases, appeared to
cause local swelling or otherwise disconnection of the dendrites
(Fig. 4H, L). Individually labeled dendrite-like processes or
segments were also seen in increasing numbers with age in the
EPL and around glomeruli (Fig. 4F–H).
The age-related increase in SBDP120 immunolabeling in the
olfactorybulbin36Tg-ADmicerelativetonon-Tgcounterpartswas
clearly visible in thresholded pseudocolor images of the region
including the MCL and EPL (see Fig. 4M). For quantitative
comparions, the data were normalized to the mean (defined as
100%)ofthe6-montholdcontrolgroup.Overall,levelsofSBDP120
IR increased with age in both the non-Tg (p=0.0027, F=8.48,
df=3, 12, one-way ANOVA) and 36Tg-AD groups (p=0.0024,
F=8.76,df=3,12).One-wayANOVAanalysisrevealedstatistically
significant genotype differences (p,0.05 to p,0.001) at all 4 age
points (p,0.0001,F=19.66,df=7, 24)(Fig. 4N).
Western Analysis of SBDP120 Levels in 36Tg-AD Relative
to non-Tg Mice
Western blot analyses were carried out to confirm the elevation
of SBDP120 in the forebrain of the transgenic mice relative to
non-Tg counterparts (n=4 per point for each age and genotype;
Fig. 5). The standardized SBDP120 signal (% of b-actin level) from
each brain was normalized to the mean (defined as 100%) of the 6
month-old non-Tg group. SBDP120 levels in the non-Tg frontal
cortex were 100613.7%, 102.9615.0%, 139.468.5% and
218.1617.9% (mean6S.D., same format below) at 6, 12, 18
and 24 months of age, respectively, showing an age-related
Figure 1. Immunohistochemical characterization of a rabbit antibody to 120 kDa aI-spectrin breakdown product (SBDP120) in
aged rat frontal cortex (FC). Panel A shows SBDP120 labeling in a subpopulation of layer V (5) cortical neurons. This cellular labeling was largely
blocked by the 5-mer (B) or the 8-mer (C) immunogenic peptide (at 0.1 mM concentration) used for antibody genesis. When both peptide forms were
included in the primary antibody incubation buffer, specific labeling in the cortex was completely eliminated (D). No labeling was seen in the absence
of the primary (E) or secondary (F) antibody (Ab). Scale bar=400 mm in A, also applying to B-F.
doi:10.1371/journal.pone.0037599.g001
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PLoS ONE | www.plosone.org 4 June 2012 | Volume 7 | Issue 6 | e37599Figure 2. Representative images showing SBDP120 immunoreactivity in the cerebral cortex, hippocampal formation and olfactory
bulb in 16- and 26-month (mo) old rats. Panel A is a low magnification image over the parietal cortex and underlying hippocampal formation,
with subregions of this figure enlarged sequentially as panels B to G. Small dot- or granule-like immunoreactive elements were seen in deep cortical
layers, especially layer V (B). These elements appear to group as perikaryal profiles around the cell boundary at high magnification (E). Much granular
labeling was seen in stratum pyramidale (s.p.) of CA1 and CA3 (C, D, F, and G). In the olfactory bulb, a row of labeled profiles was visible at low
magnification around the periphery (H), appearing as strong immunoreactive profiles around the mitral cell layer at high magnification (I, J). The
labeling consisted of aggregated granules (arrows) located at the apical dendrites and the somatodendritic junction of the mitral cells. Asterisk in ‘‘I’’
indicates a displaced mitral cell or tufted cell. Panels K-N are high-magnification images of SBDP120 labeling in sections counterstained with toluidine
blue from a 26 month-old rat. Relative to (E), larger and more densely labeled aggregated SBDP120 reactive elements were present in the cortex,
SBDP120 in Rodent Forebrain
PLoS ONE | www.plosone.org 5 June 2012 | Volume 7 | Issue 6 | e37599increase (p,0.0001, F=62.5, df=3,12). SBDP120 levels in the
frontal cortex of 36Tg-AD mice were also elevated with age
(120.0620.5%, 118.3.3617.9%, 220.6622.1% and
324.9633.6%) at the above time points (p,0.0001, F=65.6,
df=3,12). Significant differences were also found between the
transgenic and non-Tg groups at 18 (p,0.001) and 24 (p,0.001)
months of age (Fig. 5A, B).
Normalized SBDP120 levels in the non-Tg olfactory bulb were
100613.3%, 108.967.9%, 176.1629.2 and 210.1612.9 at 6, 12,
18 and 24 months of age, respectively. There was a statistically
significant increase with age (p,0.0001, F=36.2, df=3,12). In the
36Tg-AD mice, relative levels of SBDP120 in the olfactory bulb
were 126.0628.6%, 205.3625.3%, 298.0617.0 and 337.2626.1
at comparable age points, respectively, and also increased age-
dependently (p,0.0001, F=59.2, df=3,12). Significant differenc-
es between transgenic vs non-Tg groups were seen at 12, 18 and
24 months of age (p,0.001 for all points; Fig. 5C, D).
6E10, p-Tau and Active Caspase-3 Immunolabeling in
36tg-AD Forebrain
The development of amyloid plaque and p-Tau pathology in
the cerebral cortex and hippocampal formation in the 36Tg-AD
model has been described in many previous studies
[39],[40],[42],[43],[44]. In our local colony of this mouse strain,
the expression of the transgenic b-amyloid precursor protein (APP)
in pyramidal neurons, as detected by 6E10, occurs in the cerebral
cortex and hippocampus as early as 1–2 months of age, but
extracellular amyloid plaques develop largely after 20 months of
age in these forebrain areas [40]. In contrast, no 6E10-labeled
neuronal somata labeling were seen in the main olfactory bulb in
either young or old 36Tg-AD mice (Fig. 6A–F), consistent with
findings of a recent report [44]. A small amount of extracellular
Ab deposition could be detected in the olfactory bulb by 20
months of age in our colony of 36Tg-AD mice (Fig. 6B, E). By 24
months of age, a considerable amount of extracellular 6E10 IR
was present in the olfactory bulb (Fig. 6C, F). However, it should
be stressed that this plaque pathology was present over the granule
cell layer, but rarely around the outer bulb layers (the mitral cell,
external plexiform and glomerular layers (Fig. 6C, F). Thus, there
was no correlation (from regional, laminar or cellular distribution
perspectives) between SBDP120 and 6E10 immunolabeling in
36Tg-AD mice in the cerebral cortex or olfactory bulb.
p-Tau IR also appeared fairly early in our colony of the 36Tg-
AD mice, at 1–2 month of age. p-Tau labeling was most
prominent in the subiculum and CA1, expressed in the somata
and processes of principal neurons. A small population of cortical
pyramidal neurons also expressed p-Tau IR in their somata and
dendrites [40]. This overall regional and cellular pattern of p-Tau
expression was maintained at older ages (after plaque onset), as
shown in Fig. 6G–I. It should be noted that some hippocampal
and cortical pyramidal neurons showed aggregated p-Tau
reactivity resembling tangles (Fig. 6H, arrows). p-Tau immunore-
active neurons and processes were also present in layer III of the
piriform cortex in young (not shown) and old transgenic mice
(Fig. 6J, K). However, in the same immunostained section, no
somal profiles were detectable in the olfactory bulb at any age
[40], although weak IR existed in the nerve fiber layer (Fig. 6L).
Therefore, as with 6E10, there was no apparent correlation
between SBDP120 and p-Tau with respect to regional, laminar or
cellular expression pattern at a given age in the 36Tg-AD brain.
We also explored the anatomical correlation between SBDP120
and active caspase-3 labeling, using an antibody that labels active
caspase fragments in cell nuclei [41]. Immunolabeling for active
caspase-3 was carried out in both wild-type and transgenic mouse
forebrain at various ages. These experiments did not reveal
significant typical nuclear labeling of active caspase-3 in the
cerebral cortex or olfactory bulb (Fig. 6M–O, shown as examples
from a 24-month old mouse). Thus, laminar and cellular
expression of SBDP120 IR did not appear to correlate with an
overt/typical pattern of caspase-3 activation.
Discussion
SBDP120 Elevates in Aged Rodent Forebrain, and More
Robustly in 36Tg-AD Mice
Previous studies show increased levels of aII-spectrin break-
down in rodent brain during aging [31],[33],[34]. We attempted
to determine the cellular/neuronal localization and time course of
age-related SBDP elevation. We tested several rabbit and goat
antibodies to various SBDPs; many showed diffuse cellular
labeling in young rodent brain (data not shown), presumably
because of a cross-reactivity of the antibody to uncleaved aII-
spectrin [27]. The rabbit antibody to SBDP120 exhibited selective
labeling. After a vigorous validation of its specificity, this antibody
was considered suitable for use in immunohistochemical studies.
We demonstrate here that lamina and cell-specific SBDP120
labeling was present in the cortex and olfactory bulb in 16 month-
old rats. In 24–26 month-old rats, specific SBDP120 labeling was
prominent in the cortex and olfactory bulb. SBDP120 IR could be
visualized in relatively large-sized layer V perikarya and some
dendrite-like processes in aged rat cortex. Heavily labeled elements
were also consistently present around the mitral cell layer in the
olfactory bulb in aged rats. In line with these rat data, levels and
immunolabeling density of SBDP120 increased progressively with
age in both wild type and 36TG-AD mouse frontal cortex and
olfactory bulb. Protein levels and immunolabeling density of
SBDP120 in these forebrain areas were comparatively higher in
36Tg-AD mice than in their non-Tg cohorts. Together, these data
suggest that the 120 kDa aII-spectrin breakdown product is
upregulated in the forebrain with age, and that this phenomenon is
enhanced in a transgenic model of AD.
Olfactory Mitral Cells are Prone to SBDP120
Accumulation in their Apical Dendrites
The present study identifies that the olfactory bulb principal
neurons are especially vulnerable to an early-onset but aggressive
SBDP120 accumulation. Granular SBDP120 labeling appeared
first around the junction of the soma and apical dendrite, by 12
months of age in non-Tg mice but at least as early as 6 months of
age in 36Tg-AD animals. With age, these granules continued to
some clearly appearing as pyramidal cellular profiles. Small dot-like and isolated profiles (arrowheads) were also seen (K, L). In the olfactory bulb (M,
N), heavily labeled profiles in oval or fusiform shape were present around the mitral cell layer (MCL). Labeled segments were also seen in small
numbers in the external plexiform layer (EPL) (arrows in M). Diffuse labeling seen in the glomeruli appeared to be somewhat increased in 26 (M)
relative to 16 (H) month-old animals. Roman numerals denote cortical layers; WM: white matter; FC: frontal cortex; PC: parietal cortex; DG: dentate
gyrus; OB: olfactory bulb; GL: glomerular layer; GCL: granule cell layer; MCL: mitral cell layer; EPL: external plexiform layer; ML: molecular layer; s.r.:
stratum radiatum; s.l.m.: stratum lucunosum-moleculare. Scale bar =1 mm in A; equivalent to 300 mm for B-D, H, K, M; 100 mm for E-G, I, L, and 50 mm
for J, N.
doi:10.1371/journal.pone.0037599.g002
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PLoS ONE | www.plosone.org 6 June 2012 | Volume 7 | Issue 6 | e37599Figure 3. Images and densitometry showing increased SBDP120 immunolabeling in the frontal cortex of 36Tg-AD mice relative to
wild type (Non-Tg) cohorts at 12 and 24 month of age. Panels A–D are low magnification images illustrating the overall pattern of labeling in
the forebrain. Labeling in the frontal cortical area was progressively enhanced with aging and transgenic status (E–M). Labeled profiles were hard to
detect in the cortex in 12-month old non-Tg mice (E, I), in contrast to 36Tg-AD mice (G, L). SBDP120 labeling was clearly present in the cortex of 24
month-old non-Tg (F, J) mice, but was dramatically increased in 36Tg-AD (M) mice. The labeled elements were granular but frequently appeared to
be arranged around cell borders in 24 month-old non-Tg and 12 month-old 36Tg-AD cortex (J, L). In 24 month-old transgenic mice the labeling was
aggregated around the cell perimeter as well as being present in the somata of pyramidal cortical neurons (M). Panel N is a psudocolor image with a
background cutoff illustrating the age and genotype differences in relative density of SBDP120 reactivity in cortical layer V. These differences are
expressed quantitatively in the bar graph (O). *p,0.005. Scale bar=1 mm in A applying to B-D; equal to 200 mm for E–H and 50 mm for I–M.
doi:10.1371/journal.pone.0037599.g003
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PLoS ONE | www.plosone.org 7 June 2012 | Volume 7 | Issue 6 | e37599Figure 4. Images and densitometry showing increased SBDP120 immunolabeling in the olfactory bulb of 36Tg-AD mice relative to
non-transgenic (Non-Tg) cohorts from 6 to 24 month of age. Panels A-H illustrate the evolution of immunolabeling pattern around the mitral
cell layer (MCL). In non-Tg mice, granules of strong SBDP120 immunoreactivity appeared in mitral cell somata at 12 months of age (B, arrows) and
progressively increased at older ages (C, D, J); such granular elements were no seen in 6-month old non-Tg mice (A, I). In contrast, in the 36Tg-AD
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PLoS ONE | www.plosone.org 8 June 2012 | Volume 7 | Issue 6 | e37599accumulate, largely in the apical dendrites. In old animals,
SBDP120 immunolabeled granules sometimes filled in the entire
apical dendrite of a mitral cell and seemed to cause local swelling
in some cases. To our knowledge, this type of age-related mitral
cell lesion has not been previously documented in literature. A
potential reason for this exceptional SBDP accumulation might be
that the mitral cell dendrites are postsynaptic to a very plastic
presynaptic system, olfactory nerve terminals that undergo
constant renewal [45]. One may expect that there is a continuing
process of dynamic membrane remodeling on mitral cell dendrites
due to the high plasticity of the first olfactory synaptic relay. Such
a process requires a high rate of spectrin assembly and disassembly
in the dendrites, which could lead to a buildup of SBDPs [16].
Other possibilities may include that the mitral cells have a less
efficient calcium buffering system and/or autophagy-lysosomal
clearance system. Of note, the mitral cells in human are vulnerable
to age-related neurodegeneration, which is exaggerated in AD
[46],[47]. Future studies will be needed to determine if there is a
temporal/causal relationship between SBDP120 elevation and
mitral cell death.
Mechanistic Considerations for Intraneuronal SBDP120
Buildup
The molecular mechanism underlying age-dependent intraneu-
ronal SBDP120 accumulation in normal rodents and 36Tg-AD
mice is currently unknown. SBDP120 is derived from caspases-3-
mediated aII-spectrin cleavage, as has been shown in conditions
promoting apoptotic and necrotic cell death conditions [19]. In the
present study we did not detect a significant amount of nuclear
labeling of active caspase-3 in the cortex or olfactory bulb. It
should be noted that pharmacological studies indicate that
caspase-3 activation is involved in many physiological cellular
events under normal conditions, including modulation of long-
term potentiation and other forms of synaptic plasticity, which are
not associated with an overt presence of active caspase-3 fragments
[48],[49],[50]. In addition, a degree of nuclear labeling of active
caspase-3 can be seen in apparently healthy neurons in some brain
regions [41],[48],[49],[51]. We hypothesize that a low dose of
non-apoptotic caspase-3 activation may exist in vulnerable
neuronal populations such as cortical and olfactory projective
neurons [52], leading to the observed intraneuronal SBDP120
elevation. This level caspase-3 activation is below the threshold of
detection by antibodies and may, perhaps, be involved in
modulation of neuroplasticity rather than apoptosis. Such a notion
is consistent with the finding that SBDP120 accumulation
progresses over an extended period, given the initial appearance
of labeling before mid-age.
Why do 36Tg-AD mice show earlier intraneuronal SBDP120
labeling relative to non-Tg cohorts? This genotype-related
difference does not appear to be directly caused by amyloid or
tau pathology. In the cerebral cortex, SBDP120 labeling does
emerge initially in the deep layers that exhibit prominent
transgenic APP expression (based on 6E10 cellular labeling)
[40],[42],[43]. Conversely, the olfactory mitral cells do not exhibit
impressive 6E10 or p-Tau labeling in either young or aged
transgenic mice [44]. Thus, other molecular/cellular disturbances
mice labeled granules were present in most mitral cells at 6 month of age (E), and their number and labeling intensity increased in older animals (F-
H). There was a progressive aggregation of the labeled granules in the proximal area of the apical dendrites with age (F-H, K, and L). Psudocolor
images (M) show an overview of the age and genotype differences in relative density of SBDP120 reactivity. The age-related increase in labeling
density measured over the mitral cell and external plexiform layer is quantified in panel N. *p,0.005. Scale bar=200 mm in A applying to B-H;
equivalent to 25 mm for I-L.
doi:10.1371/journal.pone.0037599.g004
Figure 5. Age-related elevation of SBDP120 levels in the cerebral cortex and olfactory bulb of 36Tg-AD relative to non-transgenic
mice. Panels A and C show representative western blot results from one set of animals at the 4 age points as indicated. Graphs B and D show the
quantitative data. Levels of SBDP120 were higher in transgenics relative to controls in the cortex at 18 and 24 months of age, and in the olfactory
bulb from 12 months of age onward. N=4 per data point. *p,0.001.
doi:10.1371/journal.pone.0037599.g005
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PLoS ONE | www.plosone.org 9 June 2012 | Volume 7 | Issue 6 | e37599Figure 6. Images of immunolabeling with the b-amyloid (Ab) antibody 6E10, phosphorylated tau (pTau) and active caspase-3 in the
forebrain of 36Tg-AD mice. 6E10 labeled cortical neurons in layers V and VI in the frontal cortex (FC) in 18- (A), 20- (B) and 24- (C) month old
transgenics. Extracellular Ab deposition appeared largely as diffuse plaques that were present in the cortex by 20 (B), but became common at 24 (C),
months of age. Note the large number of plaques in the septum of both 20- and 24-month old transgenic mice. In the olfactory bulb, diffuse plaques
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PLoS ONE | www.plosone.org 10 June 2012 | Volume 7 | Issue 6 | e37599in the transgenic brain must be responsible for the accelerated aII-
spectrin breakdown. Among the potential candidates, oxidative
stress [53],[54] or the calcium buffering deficits inherent in
transgenic AD animal models are of particular interest [55].
Specifically, mutations in presenilins have been associated with
calcium leakage and deregulation. This chronic calcium stress
might activate calcium-sensitive proteases such as calpain and
caspases to levels triggering spectrin degradation [56],[57],[58].
In summary, the present study identifies an age-related
occurrence of the aII-spectrin cleavage product SBDP120 in
forebrain neurons in normal laboratory rodents, which is
accelerated in the triple transgenic model of AD. The olfactory
bulb mitral cells are particularly vulnerable to this age-dependent
neuronal change. The results suggest that the metabolism of a key
membrane protein can manifest as an early neuronal alteration
during brain aging and under chronic neurodegenerative condi-
tions, perhaps as the consequence of dysfunctional calcium-
sensitive protease signaling.
Author Contributions
Conceived and designed the experiments: XXY AJ. Performed the
experiments: YC HXZ JML. Analyzed the data: YC HXZ JML XXY.
Contributed reagents/materials/analysis tools: XXY JS RH KKWW AJ
PRP GMR XGL. Wrote the paper: XXY.
References
1. Bennett V (1982) The molecular basis for membrane - cytoskeleton association
in human erythrocytes. J Cell Biochem 18:49–65.
2. Isayama T, Goodman SR, Zagon IS (1991) Spectrin isoforms in the mammalian
retina. J Neurosci 11: 3531–3538.
3. Bennett V, Baines AJ (2001) Spectrin and ankyrin-based pathways: metazoan
inventions for integrating cells into tissues. Physiol Rev 81:1353–1392.
4. Voas MG, Lyons DA, Naylor SG, Arana N, Rasband MN, et al. (2007) aII-
Spectrin is essential for assembly of the nodes of Ranvier in myelinated axons.
Curr Biol 17:562–568.
5. Siman R, Toraskar N, Dang A, McNeil E, McGarvey M, et al. (2009) A panel of
neuron-enriched proteins as markers for traumatic brain injury in humans.
J Neurotrauma 26:1867–1877.
6. Baines AJ (2010) Evolution of the spectrin-based membrane skeleton. Transfus
Clin Biol 17:95–103.
7. Hund TJ, Koval OM, Li J, Wright PJ, Qian L, et al. (2010) A b(IV)-spectrin/
CaMKII signaling complex is essential for membrane excitability in mice. J Clin
Invest 120:3508–3519.
8. Susuki K, Raphael AR, Ogawa Y, Stankewich MC, Peles E, et al. (2011)
Schwann cell spectrins modulate peripheral nerve myelination. Proc Natl Acad
Sci USA 108: 8009–80014.
9. Schafer DP, Jha S, Liu F, Akella T, McCullough LD, et al. (2009) Disruption of
the axon initial segment cytoskeleton is a new mechanism for neuronal injury.
J Neurosci 29: 13242–13254.
10. Pielage J, Fetter RD, Davis GW (2006) A postsynaptic spectrin scaffold defines
active zone size, spacing, and efficacy at the Drosophila neuromuscular junction.
J Cell Biol 175:491–503.
11. Hu ¨lsmeier J, Pielage J, Rickert C, Technau GM, Kla ¨mbt C, et al. (2007) Distinct
functions of alpha-Spectrin and beta-Spectrin during axonal pathfinding.
Development 134:713–722.
12. Grubb MS, Burrone J (2010) Building and maintaining the axon initial segment.
Curr Opin Neurobiol 20:481–488.
13. Ramser EM, Buck F, Schachner M, Tilling T (2010) Binding of aII spectrin to
14-3-3beta is involved in NCAM-dependent neurite outgrowth. Mol Cell
Neurosci 45:66–74.
14. Stankewick MC, Gwynn B, Ardito T, Ji L, Kim J, et al. (2010) Targeted deletion
of betaIII spectrin impairs synaptogenesis and generates ataxic and seizure
phenotypes. Proc Natl Acad Sci USA 107:6022–6027.
15. Westphal D, Sytnyk V, Schachner M, Leshchyns’ka I (2010) Clustering of the
neural cell adhesion molecule (NCAM) at the neuronal cell surface induces
caspase-8- and -3-dependent changes of the spectrin meshwork required for
NCAM-mediated neurite outgrowth. J Biol Chem 285: 42046–42057.
16. Bingol B, Sheng M (2011) Deconstruction for reconstruction: the role of
proteolysis in neural plasticity and disease. Neuron 69:22–32.
17. Nestor MW, Cai X, Stone MR, Bloch RJ, Thompson SM (2011) The actin
binding domain of bI-spectrin regulates the morphological and functional
dynamics of dendritic spines. PLoS One 6: e16197.
18. Warren MW, Zheng W, Kobeissy FH, Cheng LM, Hayes RL, et al. (2007)
Calpain- and caspase-mediated alphaII-spectrin and tau proteolysis in rat
cerebrocortical neuronal cultures after ecstasy or methamphetamine exposure.
Int J Neuropsychopharmacol 10: 479–489.
19. Zhang Z, Larner SF, Liu MC, Zheng W, Hayes RL, Wang KK (2009) Multiple
alphaII-spectrin breakdown products distinguish calpain and caspase dominated
necrotic and apoptotic cell death pathways. Apoptosis 14:1289–1298.
20. Nath R, Huggins M, Glantz SB, Morrow JS, McGinnis K, et al. (2000)
Development and characterization of antibodies specific to caspase-3-produced
alpha II-spectrin 120 kDa breakdown product: marker for neuronal apoptosis.
Neurochem Int 37:351–361.
21. Newcomb JK, Pike BR, Zhao X, Hayes RL (2000) Concurrent assessment of
calpain and caspase-3 activity by means of western blots of protease-specific
spectrin breakdown products. Methods Mol Biol 144:219–223.
22. Brophy GM, Pineda JA, Papa L, Lewis SB, Valadka AB, et al. (2009) aII-
Spectrin breakdown product cerebrospinal fluid exposure metrics suggest
differences in cellular injury mechanisms after severe traumatic brain injury.
J Neurotrauma 26:471–479.
23. Weiss ES, Wang KK, Allen JG, Blue ME, Nwakanma LU, et al. (2009) Alpha II-
spectrin breakdown products serve as novel markers of brain injury severity in a
canine model of hypothermic circulatory arrest. Ann Thorac Surg 88:543–550.
24. Mondello S, Robicsek SA, Gabrielli A, Brophy GM, Papa L, et al. (2010) aII-
spectrin breakdown products (SBDPs): diagnosis and outcome in severe
traumatic brain injury patients. J Neurotrauma 27: 1203–1213.
25. Bi X, Chang V, Siman R, Tocco G, Baudry M (1996) Regional distribution and
time-course of calpain activation following kainate-induced seizure activity in
adult rat brain. Brain Res 726: 98–108.
26. Tamada Y, Nakajima E, Nakajima T, Shearer TR, Azuma M (2005) Proteolysis
of neuronal cytoskeletal proteins by calpain contributes to rat retinal cell death
induced by hypoxia. Brain Res 1050:148–155.
27. Hwang IK, Yoo KY, Kim DW, Li H, Park OK, et al. (2008) AlphaII-spectrin
breakdown product increases in principal cells in the gerbil main olfactory bulb
following transient ischemia. Neurosci Lett 435:251–256.
28. Peterson C, Vanderklish P, Seubert P, Cotman C, Lynch G (1991) Increased
spectrin proteolysis in fibroblasts from aged and Alzheimer donors. Neurosci
Lett 121:239–243.
29. Gaczyn ´ska M (1992) Changes in proteolytic susceptibility of human erythrocyte
membrane proteins during red blood cell aging. Cytobios 72:197–200.
30. Lee A, Morrow JS, Fowler VM (2001) Caspase remodeling of the spectrin
membrane skeleton during lens development and aging. J Biol Chem
276:20735–20742.
31. Bahr BA, Vanderklish PW, Ha LT, Tin MT, Lynch G (1991) Spectrin
breakdown products increase with age in telencephalon of mouse brain.
Neurosci Lett 131:237–240.
32. Bernath E, Kupina N, Liu MC, Hayes RL, Meegan C, et al. (2006) Elevation of
cytoskeletal protein breakdown in aged Wistar rat brain. Neurobiol Aging
27:624–632.
33. Rohn TT, Head E (2008) Caspase activation in Alzheimer’s disease: early to rise
and late to bed. Rev Neurosci 2008, 19:383–393.
34. Yan XX, Jeromin A (2012) Spectrin breakdown products (SBDPs) as potential
biomarkers for neurodegenerative diseases. Curr Tran Geriatr Gerontol Rep,
DOI 10.1007/s13670-012-0009-2
35. Masliah E, Iimoto DS, Saitoh T, Hansen LA, Terry RD (1990) Increased
immunoreactivity of brain spectrin in Alzheimer disease: a marker for synapse
loss? Brain Res 531:36–44.
appeared in the granule cell layer in 24 month-old animals (C, F); no 6E10 labeled neurons were seen in the olfactory bulb (OB) at any age point (D-F).
Panels G-L show p-Tau labeling in the cortex, hippocampal formation and olfactory bulb in a 24-month old animal. Distinct labeling was seen in
hippocampal CA1 pyramidal neurons and their processes, including axons in the alveus (Alv; G, H). A few CA1 pyramidal neurons exhibited tangle-like
pathology (arrows in H). A small number of cortical pyramidal neurons also showed clear p-Tau immunoreactivity (I). p-Tau immunoreactive somata
were not seen in the main olfactory bulb (J, L), but were present in the deep part of the piriform cortex (J, K). In contrast, p-Tau labeling was seen in
the nerve fiber layer (NFL; L). No overt nuclear labeling of active caspase-3 was detectable in the forebrain in 24-month old animals (M-O). RMS: rostral
migratory stream. Other abbreviations are defined in the legend for Figure 2. Scale bar=2 mm in A applying to B-C, M; equal to 1 mm in G, 100 mmi n
F, and 200 mm for remaining panels.
doi:10.1371/journal.pone.0037599.g006
SBDP120 in Rodent Forebrain
PLoS ONE | www.plosone.org 11 June 2012 | Volume 7 | Issue 6 | e3759936. Ayala-Grosso C, Tam J, Roy S, Xanthoudakis S, Da Costa D, et al. (2006)
Caspase-3 cleaved spectrin colocalizes with neurofilament-immunoreactive
neurons in Alzheimer’s disease. Neuroscience 141:863–874.
37. Higuchi M, Iwata N, Matsuba Y, Takano J, Suemoto T, et al. (2012)
Mechanistic involvement of the calpain-calpastatin system in Alzheimer
neuropathology. FASEB J 26:1204–1217.
38. Liang B, Duan BY, Zhou XP, Gong JX, Luo ZG (2010) Calpain activation
promotes BACE1 expression, amyloid precursor protein processing, and
amyloid plaque formation in a transgenic mouse model of Alzheimer disease.
J Biol Chem 285:27737–27744.
39. Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, et al. (2003) Triple-
transgenic model of Alzheimer’s disease with plaques and tangles: intracellular
Abeta and synaptic dysfunction. Neuron 39:409–421.
40. Cai Y, Zhang XM, Macklin LN, Cai H, Luo XG, et al. (2012) BACE1 elevation
is involved in amyloid plaque development in the triple transgenic model of
Alzheimer’s disease: Differential Ab antibody labeling of early-onset axon
terminal pathology. Neurotox Res 21:160–174.
41. Yan XX, Najbauer J, Woo CC, Dashtipour K, Ribak CE, et al. (2011)
Expression of active caspase-3 in mitotic and postmitotic cells of the rat
forebrain. J Comp Neurol 433:4–22.
42. Mastrangelo MA, Bowers WJ (2008) Detailed immunohistochemical character-
ization of temporal and spatial progression of Alzheimer’s disease-related
pathologies in male triple-transgenic mice. BMC Neurosci 9:81.
43. Winton MJ, Lee EB, Sun E, Wong MM, Leight S, et al. (2011) Intraneuronal
APP, not free Ab peptides in 36Tg-AD mice: implications for tau versus Ab-
mediated Alzheimer neurodegeneration. J Neurosci 31:7691–7699.
44. Cassano T, Romano A, Macheda T, Colangeli R, Cimmino CS, et al. (2011)
Olfactory memory is impaired in a triple transgenic model of Alzheimer disease.
Behav Brain Res 224:408–412.
45. Graziadei PP, Graziadei GA (1979) Neurogenesis and neuron regeneration in
the olfactory system of mammals. I. Morphological aspects of differentiation and
structural organization of the olfactory sensory neurons. J Neurocytol 8:1–18.
46. Bhatnagar KP, Kennedy RC, Baron G, Greenberg RA (1987) Number of mitral
cells and the bulb volume in the aging human olfactory bulb: a quantitative
morphological study. Anat Rec 218: 73–87.
47. Struble RG, Clark HB (1992) Olfactory bulb lesions in Alzheimer’s disease.
Neurobiol Aging 13: 469–473.
48. Algeciras-Schimnich A, Barnhart BC, Peter ME (2002) Apoptosis-independent
functions of killer caspases. Curr Opin Cell Biol 14:721–726.
49. Lamkanfi M, Festjens N, Declercq W, Vanden Berghe T, Vandenabeele P, et al.
(2007) Caspases in cell survival, proliferation and differentiation. Cell Death
Differ 14:44–55.
50. Kudryashova IV, Onufriev MV, Kudryashov IE, Gulyaeva NV (2009) Caspase-
3 activity in hippocampal slices reflects changes in synaptic plasticity. Neurosci
Behav Physiol 39:13–20.
51. Lynch G, Baudry M (1987) Brain spectrin, calpain and long-term changes in
synaptic efficacy. Brain Res Bull 18:809–815.
52. Ennis M, Linster C, Aroniadou-Anderjaska V, Ciombor K, Shipley MT (1998)
Glutamate and synaptic plasticity at mammalian primary olfactory synapses.
Ann N Y Acad Sci 855:457–466.
53. Keil U, Hauptmann S, Bonert A, Scherping I, Eckert A, et al. (2006)
Mitochondrial dysfunction induced by disease relevant AbetaPP and tau protein
mutations. J Alzheimers Dis 9: 139–146.
54. Resende R, Moreira PI, Proenc ¸a T, Deshpande A, Busciglio J, et al. (2008) Brain
oxidative stress in a triple-transgenic mouse model of Alzheimer disease. Free
Radic Biol Med 44:2051–2057.
55. Camandola S, Mattson MP (2011) Aberrant subcellular neuronal calcium
regulation in aging and Alzheimer’s disease. Biochim Biophys Acta 1813:965–
973.
56. Leissring MA, LaFerla FM, Callamaras N, Parker I (2001) Subcellular
mechanisms of presenilin-mediated enhancement of calcium signaling. Neuro-
biol Dis 8:469–478.
57. Lopez JR, Lyckman A, Oddo S, Laferla FM, Querfurth HW, et al. (2008)
Increased intraneuronal resting [Ca2+] in adult Alzheimer’s disease mice.
J Neurochem 105:262–271.
58. Zhang H, Sun S, Herreman A, De Strooper B, Bezprozvanny I (2010) Role of
presenilins in neuronal calcium homeostasis. J Neurosci 30: 8566–8580.
SBDP120 in Rodent Forebrain
PLoS ONE | www.plosone.org 12 June 2012 | Volume 7 | Issue 6 | e37599